JW Choongwae Pharm, applied for product approval of’Rivarojet’, a new complex drug for hyperlipidemia
JW Choongwae Pharmaceutical’s new complex drug for hyperlipidemia, Rivarojet product license application
JW Choongwae Pharmaceutical proves lipid-improving effect as a result of Phase 3 clinical trial of RivaroJet’NDA application’
JW Choongwae Pharmaceutical proves the effect of improving lipids in phase 3 clinical trials of ribarojet
JW Choongwae Pharmaceutical, “Two times more effective than remdesivir, the treatment substance for Corona 19” Spur development of treatment
